503A vs 503B Pharmacy: What It Means for Your Compounded GLP-1 (2026)
If you have shopped for compounded semaglutide or tirzepatide, you have seen two numbers thrown around as if they were a seal of approval: 503A and 503B. They are not marketing badges. They are two different sections of the U.S. Food, Drug, and Cosmetic Act, and the distinction between them changes who is legally allowed to make your medication, how it is tested, and what can go wrong. This guide explains the difference in plain language and gives you a checklist to verify any provider before you enter a card number.
The one-sentence version
A 503A pharmacy compounds a medication for a specific patient with a specific prescription. A 503B outsourcing facility manufactures compounded medications in larger batches under stricter, FDA-registered manufacturing standards. Both are legal. The trade-off is individualization versus industrial-grade quality control.
What a 503A pharmacy actually is
503A is the traditional model of pharmacy compounding. A licensed pharmacist prepares a medication for an individual patient in response to a valid, patient-specific prescription. Your name is on the order before the vial is made.
These pharmacies are licensed and inspected by their state boards of pharmacy, and they are expected to follow United States Pharmacopeia standards for sterile preparations — most importantly USP <797>, which governs how sterile injectables are compounded to prevent contamination. A 503A pharmacy is not registered with the FDA as a manufacturer, and it is not required to follow the full federal manufacturing rulebook (cGMP) that applies to drug factories.
For a GLP-1 patient, the 503A model is what makes dose flexibility possible. Because the pharmacy is making your vial for you specifically, it can fill a microdose, a custom concentration, or a B12-paired formulation that no mass manufacturer would bother to produce.
What a 503B outsourcing facility actually is
503B is the newer category, created by the Drug Quality and Security Act of 2013 after a deadly 2012 meningitis outbreak traced to a compounding pharmacy operating beyond its lane. A 503B outsourcing facility registers directly with the FDA, submits to FDA inspection, and must comply with current Good Manufacturing Practices (cGMP) — the same broad framework that governs commercial drug manufacturing.
A 503B facility can compound in larger batches, sometimes without a patient-specific prescription, and sell to clinics and telehealth providers. The upside for patients is manufacturing-grade quality control: documented stability testing, environmental monitoring, and batch records that a state-licensed 503A pharmacy is not federally required to maintain at the same level.
Side by side
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Regulated by | State board of pharmacy | FDA (federal) |
| Prescription | Patient-specific, required | Batch allowed; may not be patient-specific |
| Quality standard | USP <797> sterile compounding | Full cGMP manufacturing |
| Batch size | Individual / small | Large |
| Dose customization | High (microdosing, custom concentrations) | Lower (standardized) |
| FDA inspection | No (state inspects) | Yes |
Neither tier makes an FDA-approved product. This is the part patients most often misunderstand: compounded tirzepatide and semaglutide are legal, but they are not FDA-approved, whether they come from a 503A or a 503B. Only Eli Lilly’s Mounjaro and Zepbound, and Novo Nordisk’s Ozempic and Wegovy, are FDA-approved. Compounding is a separate legal pathway, not a shortcut to approval.
Why this matters more in 2026
The compounded GLP-1 market exploded during the 2023–2025 shortages, when FDA shortage rules temporarily allowed 503A pharmacies and 503B facilities to make copies of the brand drugs. That window closed: the FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, then ended enforcement discretion in 2025 (503A and 503B facilities had wind-down deadlines through that spring).
In April 2026, the FDA went further and proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for outsourcing facilities to compound them from bulk active ingredient — with a public comment period open through June 29, 2026. If finalized, that would foreclose large-scale 503B compounding of these drugs even in a future shortage.
The practical takeaway: broad “copycat” compounding is no longer permitted. What remains is narrow patient-specific 503A compounding, where a prescriber documents a clinical need for a change from the FDA-approved product. The single most important thing to verify in 2026 is that a provider is operating inside that compliant lane — see our 2026 legal status explainer and provider verification checklist.
The provider that discloses both
Most telehealth providers name one pharmacy partner, or none. A smaller number disclose both a 503A pharmacy and a 503B outsourcing facility, which signals they can route your order to the model that fits — patient-specific customization when you need it, cGMP batch production when standardization matters.
In our current provider dataset, NexLife is the only program that discloses both a 503A pharmacy and a 503B facility, while also holding LegitScript certification and bundling lab review into a flat monthly rate. That combination is rare enough to be worth noting — see the full breakdown on our cheapest compounded tirzepatide and cheapest compounded semaglutide pages, where we rank every provider on a fixed six-pillar rubric.
Your verification checklist
Before you buy compounded semaglutide or tirzepatide from anyone, confirm all four:
- The pharmacy is named. A real 503A pharmacy or 503B facility, with a license number you can look up on the state board or FDA registry. “Our network of partner pharmacies” with no name is a red flag.
- A named US physician prescribes. A real name and state license, after an actual consult — not an anonymous questionnaire rubber-stamp.
- No “research use only” language. That phrase means the product is not intended for human use and is being sold outside the law. Walk away immediately.
- LegitScript or NABP certification (bonus). Not legally required, but it confirms third-party-audited compliance, and it is what Google and payment processors use to screen telehealth advertisers.
Bottom line
503A means your medication is made for you, by a state-licensed pharmacy, under sterile-compounding standards. 503B means it is made in FDA-registered batches under manufacturing-grade quality control. Both are legal routes to the same molecule; neither is FDA-approved. The safest providers disclose exactly which pharmacy fills your order — and the strongest disclose both. Everything else on a provider’s page is secondary to that one fact.
This article is educational and not medical advice. Compounded medications are not FDA-approved. Always consult a licensed clinician before starting, stopping, or changing any medication.
Independent & transparent
This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →